The Centers for Medicare & Medicaid Services locked in a payment rate hike far above what was originally proposed, triggering a sharp rally in managed care stocks and offering a measure of financial stability to a program that covers more than 35 million Americans.
The federal government finalized a 2.48% average payment increase for Medicare Advantage plans in 2027 — a decision that landed well above the 0.09% rate the Trump administration had proposed in January, and one that immediately reshaped the financial outlook for the nation’s largest health insurers. The announcement, released April 6 by the Centers for Medicare & Medicaid Services, translates to more than $13 billion in additional payments flowing into privately administered Medicare plans next year, compared to the $700 million raise that had been initially planned.
The gap between the January proposal and the final rule was significant enough to constitute a relief event across the managed care sector. For months, insurer stocks had traded under pressure as investors priced in the possibility that Washington would hold firm on a rate that industry officials had called insufficient. The finalized figure changed that calculus in a matter of hours.
Why the Rate Hike Matters Beyond Wall Street
Medicare Advantage is a privately administered alternative to traditional Medicare. Under the program’s structure, the federal government pays insurers a per-member, per-month fee to cover senior healthcare. CMS adjusts these rates each year based on projected medical costs, policy priorities, enrollment trends, and insurer quality ratings. Because insurers must price their plan offerings around these government-set rates, any movement in the annual announcement carries direct consequences for what beneficiaries pay and what benefits they receive.
According to CNBC, more than half of all Medicare beneficiaries are now enrolled in Advantage plans, drawn by lower monthly premiums and supplemental benefits not covered by traditional Medicare. That enrollment base includes over 35 million Americans, making this a program with a footprint in virtually every congressional district in the country.
When CMS released its January proposal, the insurance industry warned that flat or near-flat funding would force plan exits and benefit cuts. According to analysis cited by the Better Medicare Alliance, nearly 3 million Medicare Advantage enrollees — roughly one in ten — were already forced to switch plans for 2026 due to insurer withdrawals, a record-level disruption that hit rural beneficiaries with particular severity. The finalized 2027 rate reduces the probability of a repeat.
What the Numbers Actually Mean
The 2.48% figure is a net average across the program. According to data published by FinancialContent, when accounting for estimated risk score trends in Medicare Advantage — driven by factors such as population changes and coding practices — the total effective increase amounts to approximately 4.98%. That blended figure represents the full revenue picture for insurers heading into 2027 plan design season.
The rate announcement also took into account growth in underlying healthcare costs for Medicare Advantage plans, 2026 Star Ratings for 2027 quality bonus payments, and refinements to how risk adjustment is calculated. Notably, CMS confirmed it will continue using its 2024 MA risk adjustment model for 2027, rather than adopting proposed changes that would have reduced payments significantly in certain states. Analysts had viewed those proposed changes as one of the more disruptive elements of the January advance notice.
Market Reaction Was Immediate
UnitedHealth Group stock moved from $281.36 to over $311 in the session following the announcement, according to 24/7 Wall St., while Humana climbed from $182.65 to over $198. CVS Health, whose Aetna division is one of the three largest Medicare Advantage carriers in the country, gained as well. Together, UnitedHealth, Humana, and CVS Health through Aetna cover nearly 60% of all Medicare Advantage enrollees nationwide.
The three companies entered the announcement from very different positions. UnitedHealth, the largest Medicare Advantage insurer in the country, had been deliberately trimming its plan footprint in 2026 to exit unprofitable contracts. The new rate environment gives it room to pursue that restructuring without being forced to cut member benefits to offset margin pressure. Humana had a more precarious footing heading into the announcement, having divested its commercial insurance business to concentrate entirely on Medicare Advantage and TRICARE plans. Its insurance division posted a loss of nearly $1 billion in the fourth quarter of 2025. The finalized rate provides the company with a clearer path toward margin recovery, according to Distilinfo.
Analyst Upgrades Reflect Improved Visibility
Wall Street moved quickly to adjust price targets following the CMS announcement. Bank of America raised its price target on UnitedHealth to $337 from $315. The firm also raised its target on Humana to $210 from $196, Elevance Health to $405 from $385, and Molina Healthcare to $152 from $145, according to 24/7 Wall St.
The revisions reflected improved earnings visibility rather than a fundamental reversal of the structural challenges still facing the sector. Medical utilization among seniors remains elevated, and cost trends in the program have consistently outpaced rate assumptions in recent years. Analysts at Mizuho noted the rate is meaningful relative to the initial proposal, though the extent to which it translates into margin expansion depends on whether companies continue managing expenses and benefits prudently heading into 2027.
Regulatory Scrutiny Is Not Going Away
The finalized rate hike comes with an important counterbalance. CMS has pledged to increase the number of Medicare Advantage plan audits and expand its medical coding oversight workforce. According to Distilinfo, risk adjustment accuracy — specifically concerns about upcoding, the practice of coding patients as sicker than their records support — will remain a central focus of regulatory scrutiny.
CMS Administrator Dr. Mehmet Oz stated that the agency’s vision for Medicare Advantage is a program that delivers real value for seniors while remaining a responsible use of taxpayer funds. Chris Klomp, the director of Medicare and chief counselor at HHS, described the rate announcement as designed to improve payment accuracy and strengthen competition based on quality rather than coding practices — language that signals continued federal pressure on how insurers document patient conditions.
The exclusion of diagnosis information from unlinked chart review records — diagnoses not associated with a specific patient encounter — begins in 2027, a change CMS said will reduce the financial benefit of aggressive coding practices.
What Comes Next for the Industry
By June 2026, insurers must submit their 2027 plan bids to CMS. That deadline, now set against a more favorable payment backdrop, will determine how companies price coverage, structure benefits, and decide where to compete geographically. The hope, from a beneficiary standpoint, is that a healthier rate environment slows or reverses the trend of benefit erosion and plan exits that has defined the past two years for Medicare Advantage.
The 2027 rate announcement marks a meaningful inflection point for an industry under financial strain. Whether it translates into stability for the tens of millions of Americans enrolled in these plans will depend on how insurers respond — and how diligently regulators follow through on their commitment to auditing the program’s accuracy and accountability.
Disclaimer: This article is for informational purposes only and does not constitute financial or investment advice. Readers should consult a licensed financial advisor before making investment decisions.
